



www.aphc.info



AROUND THE WORLD TABLE
ACCESS TO HCV THERAPY

M BENAZZOUZ

MOROCCO

PHC 2018 - www.aphc.info

15 & 16 January 2018 / PARIS - Palais des Congrès

Current situation of hepatitis C in Morocco

- ✓ Prevalence 1.2 % : 450 000 patients
- ✓ HCV is the main cause of chronic liver diseases :
 - 50-65% of chronic hepatitis and cirrhosis
 - 75 % of HCC
- ✓ Total number of patients treated using Peg +Riba: around 50 000
- ✓ Total number of patients treated since 2016 with DAA: 11 000

	Pourcentage
Génotype 1	56,3
Génotype 2	39,1
Génotype 3	0,3
Génotype 4	0,6

HCV in Morocco : achievements

2012	HCV Access program for patient Under the medical assistance plan (RAMED)
2015 2016	DAA available in Morocco Sofosbuvir in Dec 2015 Daclatasvir in March 2016 SOFO+LEDI : Nov 2106 SOFO +DACLA /12s : 1227 Euro SOFO + LEDI /12s : 1172 Euro
2016 2017	Preparation and validation of our national strategy against HCV 2017-2021 in collaboration with WHO <i>National guidelines for HCV management available(SMMAD dec 2017)</i>
2017	Data from national cohorts using local DAA available ERETS : Peg SOFO RIBA Dec 2016 TESORI : G2 : SOFO + DACLA Dec 2017 TESODA : G1 : SOFO + DACLA Dec 2017

EREST : G1-G2

SMMAD National cohort dec 2016

- 110 Patients
- 63 % G1 / 37% G2
- 69 % Tx exp and 31 % Tx naïve
- F3-4 : 66 %
- 81 % : Peg Sofo Riba 19 % Sofo + Riba
- Results
- **SVR 12 : 94 .5 %**
- G1 : 94 % G2 : 95.1 %
- Tx Naïve : 94.2% Tx Experienced : 94.7 %
- F0F1 : 100% F2 : 93.4 % F3F4 : 90 %

SOFO + DACLA in G1 /G2

SMMAD national cohort dec 2017

Baseline Characteristics /Results

- **458 patients**
 - 373 G1 : 81 %,4 (84 % G1b – 16 % G1a)
 - 85 G2 ; 18,6 %
 - 44.9 % treatment Naive
 - 53.7 % : Peginterferon/Ribavirin-Experienced
 - 1.7 % : Peginterferon/Ribavirin/Telaprevir –Experienced
 - 29 % were F0F1F2 and 71 % F3 F4
- Tx : SOFO + DACLA /12-24 W
- Results
 - G1 SVR 12w : 97.05 %
 - G2 SVR 12 w : 98.8 %

Plans for increase access to HCV therapy

- Screening +++
- Reduce the number and cost of diagnostic tools (PCR ,genotype...)
- Reduce more the cost of the Treatment
- Increase the number of treated patients to **20,300 /year by 2025**
- Treat all PCR positive patients ($\geq F0$)

	2015	2017	2018	2019	2025
Treated patients	3,000	5,000	10,000	15,000	20,300
fibrose stage	$\geq F2$	$\geq F0$	$\geq F0$	$\geq F0$	$\geq F0$
SVR	90%	90%	90%	90%	90%

Results expected :

>90% reduction in total infection, >65% reduction in liver related deaths and cirrhosis and >75% reduction in HCC by 2030

